12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioNTech, 4SC deal

4SC's 4SC Discovery GmbH subsidiary granted BioNTech exclusive, worldwide rights to develop and commercialize 4SC's preclinical small molecule toll-like receptor (TLR) agonists...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >